Evermore Global Advisors’s Calumet Specialty Products CLMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$13.5M Sell
801,055
-305,923
-28% -$4.93M 51.4% 1
2022
Q3
$14.2M Sell
1,106,978
-565,371
-34% -$8.11M 33.39% 1
2022
Q2
$17.4M Hold
1,672,349
30.09% 1
2022
Q1
$22.8M Hold
1,672,349
28.09% 1
2021
Q4
$22.1M Sell
1,672,349
-675,127
-29% -$8.5M 23.87% 1
2021
Q3
$18.6M Hold
2,347,476
16.33% 2
2021
Q2
$16.1M Sell
2,347,476
-45,000
-2% -$278K 14.09% 1
2021
Q1
$14.6M Buy
2,392,476
+143,267
+6% +$598K 10.28% 3
2020
Q4
$7.04M Buy
2,249,209
+34,211
+2% +$119K 7.61% 6
2020
Q3
$5.65M Buy
2,214,998
+133,436
+6% +$343K 5.12% 8
2020
Q2
$4.75M Buy
2,081,562
+431,119
+26% +$921K 2.34% 13
2020
Q1
$1.73M Buy
+1,650,443
New +$5.58M 0.71% 20

Other funds holding CLMT

Evermore Global Advisors's CLMT Position: Q4 2022 in Review

Evermore Global Advisors reduced its Calumet Specialty Products (CLMT) stake by 28% in Q4 2022, selling an estimated $4.93M and leaving 801,055 shares worth $13.5M. The position accounts for 51.4% of the portfolio, ranked #1.

Evermore Global Advisors first reported a position in CLMT in Q1 2020 and has held it in 12 quarters since. The position peaked at $22.8M in Q1 2022. 72 funds tracked by Wall St. Rank hold CLMT as of Q4 2022.

  • Evermore Global Advisors held 801,055 shares of Calumet Specialty Products worth $13.5M as of Q4 2022.
  • Evermore Global Advisors sold 305,923 Calumet Specialty Products shares in Q4 2022, an estimated $4.93M.
  • Calumet Specialty Products made up 51.4% of Evermore Global Advisors's portfolio in Q4 2022, its #1 holding.
  • Evermore Global Advisors first reported a position in Calumet Specialty Products in Q1 2020 and has held it in 12 quarters since.
  • Evermore Global Advisors's Calumet Specialty Products position peaked at $22.8M in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q4 2022.

Based on Evermore Global Advisors's 13F filing for Q4 2022, filed 18 Jan 2023.